JP2007246474A5 - - Google Patents

Download PDF

Info

Publication number
JP2007246474A5
JP2007246474A5 JP2006074822A JP2006074822A JP2007246474A5 JP 2007246474 A5 JP2007246474 A5 JP 2007246474A5 JP 2006074822 A JP2006074822 A JP 2006074822A JP 2006074822 A JP2006074822 A JP 2006074822A JP 2007246474 A5 JP2007246474 A5 JP 2007246474A5
Authority
JP
Japan
Prior art keywords
group
hydrogen atom
alkyl
aryl
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006074822A
Other languages
Japanese (ja)
Other versions
JP2007246474A (en
JP5243696B2 (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2006074822A priority Critical patent/JP5243696B2/en
Priority claimed from JP2006074822A external-priority patent/JP5243696B2/en
Publication of JP2007246474A publication Critical patent/JP2007246474A/en
Publication of JP2007246474A5 publication Critical patent/JP2007246474A5/ja
Application granted granted Critical
Publication of JP5243696B2 publication Critical patent/JP5243696B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (2)

下記一般式(I)
Figure 2007246474
〔式中、Aは下式
Figure 2007246474
{式中、
1及びR2は同一又は異なって、水素原子、アルキル基、アリール基、ヘテロアリール基、ハロゲン原子、ハロアルキル基、アルキルオキシ基、ハロアルキルオキシ基、シアノ基、ニトロ基を;
3及びR4は同一又は異なって、水素原子又はアルキル基を示し、又はR3及びR4は互いに結合してシクロアルキル基を形成し;
5は水素原子又はアルキル基を;
6は水素原子又はアルキル基を;
7はアルキル基、ハロアルキル基又はアリール基を;
Qは酸素原子又は硫黄原子を示す。なお、前記基のうち、アルキル基、アリール基は、それぞれ置換基を有していてもよい。}を示し;
nは1〜5の整数を;
Yは酸素原子、硫黄原子、−NR8−、−CONR8−、−NR8CO−又はNHCONR8−(式中、R8は水素原子、アルキル基、アリール基、ヘテロアリール基、シクロアルキルアルキル基、アリールアルキル基、アリールアルケニル基、アリールオキシアルキル基又はヘテロアリールアルキル基を示す。)を;
Zはアリール基、ヘテロアリール基、アリールアルキル基、ヘテロアリールアルキル基又はシクロアルキル基を示す。
なお、前記基のうち、アルキル基、アリール基、ヘテロアリール基、シクロアルキルアルキル基、アリールアルキル基、アリールアルケニル基、アリールオキシアルキル基又はヘテロアリールアルキル基は、それぞれ置換基を有していてもよい。〕で表されるベンゼン誘導体若しくはその薬剤上許容される塩又はそれらの水和物若しくは溶媒和物。
The following general formula (I)
Figure 2007246474
[In the formula, A is the following formula.
Figure 2007246474
{Where
R 1 and R 2 are the same or different and each represents a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, a halogen atom, a haloalkyl group, an alkyloxy group, a haloalkyloxy group, a cyano group, or a nitro group;
R 3 and R 4 are the same or different and represent a hydrogen atom or an alkyl group, or R 3 and R 4 are bonded to each other to form a cycloalkyl group;
R 5 represents a hydrogen atom or an alkyl group;
R 6 represents a hydrogen atom or an alkyl group;
R 7 represents an alkyl group, a haloalkyl group or an aryl group;
Q represents an oxygen atom or a sulfur atom. Of the above groups, the alkyl group and the aryl group each may have a substituent. }
n is an integer from 1 to 5;
Y is an oxygen atom, a sulfur atom, —NR 8 —, —CONR 8 —, —NR 8 CO— or NHCONR 8 — (wherein R 8 is a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, a cycloalkylalkyl. A group, an arylalkyl group, an arylalkenyl group, an aryloxyalkyl group or a heteroarylalkyl group);
Z represents an aryl group, heteroaryl group, arylalkyl group, heteroarylalkyl group or cycloalkyl group.
Of the above groups, the alkyl group, aryl group, heteroaryl group, cycloalkylalkyl group, arylalkyl group, arylalkenyl group, aryloxyalkyl group or heteroarylalkyl group may each have a substituent. Good. Or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.
請求項1に記載のベンゼン誘導体若しくはその薬学上許容される塩又はそれらの水和物若しくは溶媒和物を有効成分として含有する高脂血症の予防及び/又は治療薬。A prophylactic and / or therapeutic drug for hyperlipidemia comprising the benzene derivative according to claim 1 or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof as an active ingredient.
JP2006074822A 2006-03-17 2006-03-17 Benzene derivatives Expired - Fee Related JP5243696B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006074822A JP5243696B2 (en) 2006-03-17 2006-03-17 Benzene derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006074822A JP5243696B2 (en) 2006-03-17 2006-03-17 Benzene derivatives

Publications (3)

Publication Number Publication Date
JP2007246474A JP2007246474A (en) 2007-09-27
JP2007246474A5 true JP2007246474A5 (en) 2009-01-22
JP5243696B2 JP5243696B2 (en) 2013-07-24

Family

ID=38591139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006074822A Expired - Fee Related JP5243696B2 (en) 2006-03-17 2006-03-17 Benzene derivatives

Country Status (1)

Country Link
JP (1) JP5243696B2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
FR2917086B1 (en) * 2007-06-05 2009-07-17 Galderma Res & Dev NOVEL 3-PHENYL ACRYLIC ACIDIC ACID DERIVATIVES OF PPAR TYPE RECEPTORS, THEIR METHOD OF PREPARATION AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS.
FR2917084B1 (en) * 2007-06-05 2009-07-17 Galderma Res & Dev NOVEL 3-PHENYL PROPANOIC ACID DERIVATIVES OF PPAR-TYPE RECEPTORS, THEIR METHOD OF PREPARATION AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS
JP5508260B2 (en) 2007-07-09 2014-05-28 アストラゼネカ アクチボラグ Morpholinopyrimidine derivatives used for diseases related to mTOR kinase and / or P13K
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131951A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
SA111320519B1 (en) 2010-06-11 2014-07-02 Astrazeneca Ab Pyrimidinyl Compounds for Use as ATR Inhibitors
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013122028A1 (en) * 2012-02-13 2013-08-22 武田薬品工業株式会社 Aromatic ring compound
JPWO2015163435A1 (en) * 2014-04-24 2017-04-20 田辺三菱製薬株式会社 Novel 2-amino-pyridine and 2-amino-pyrimidine derivatives and their pharmaceutical use
CN115477588B (en) * 2022-09-30 2023-11-17 中国药科大学 Lipid regulating compound based on cholesterol reverse transport path, synthesis method and application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
JP4383177B2 (en) * 2002-03-01 2009-12-16 スミスクライン ビーチャム コーポレーション hPPAR activator
US6653334B1 (en) * 2002-12-27 2003-11-25 Kowa Co., Ltd. Benzoxazole compound and pharmaceutical composition containing the same

Similar Documents

Publication Publication Date Title
JP2007246474A5 (en)
JP2007508359A5 (en)
JP2017519781A5 (en)
JP2019529490A5 (en)
JP2009263394A5 (en)
JP2010501478A5 (en)
JP2005519932A5 (en)
JP2008505157A5 (en)
JP2012533546A5 (en)
JP2017524025A5 (en)
JP2005539088A5 (en)
JP2005053931A5 (en)
JP2003519676A5 (en)
JP2007508362A5 (en)
JP2007538031A5 (en)
JP2010535722A5 (en)
JP2009530306A5 (en)
JP2009502770A5 (en)
RU2007108863A (en) Pyrazole derivatives for the treatment of conditions mediated by activation of an adenosine A2B or A3 receptor
JP2007520440A5 (en)
JP2010504908A5 (en)
JP2005289914A5 (en)
JP2005527542A5 (en)
JP2007517826A5 (en)
JP2003534359A5 (en)